Shaping the landscape of immune oncology in hepatocellular carcinoma

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Milan, Italy; Humanitas Cancer Center, Humanitas Clinical and Research Center, 20089 Rozzano, Milan, Italy.
² Humanitas Cancer Center, Humanitas Clinical and Research Center, 20089 Rozzano, Milan, Italy. Electronic address: lorenza.rimassa@cancercenter.humanitas.it.

Comment

Nicola Personeni et al. Lancet Oncol. 2018 Jul.

. 2018 Jul;19(7):855-856.

doi: 10.1016/S1470-2045(18)30383-8. Epub 2018 Jun 3.

¹ Department of Biomedical Sciences, Humanitas University, Milan, Italy; Humanitas Cancer Center, Humanitas Clinical and Research Center, 20089 Rozzano, Milan, Italy.
² Humanitas Cancer Center, Humanitas Clinical and Research Center, 20089 Rozzano, Milan, Italy. Electronic address: lorenza.rimassa@cancercenter.humanitas.it.

No abstract available

Comment on

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Zhu AX, et al. Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Lancet Oncol. 2018. PMID: 29875066 Clinical Trial.